JP2017505313A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505313A5 JP2017505313A5 JP2016548269A JP2016548269A JP2017505313A5 JP 2017505313 A5 JP2017505313 A5 JP 2017505313A5 JP 2016548269 A JP2016548269 A JP 2016548269A JP 2016548269 A JP2016548269 A JP 2016548269A JP 2017505313 A5 JP2017505313 A5 JP 2017505313A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- fluorine
- optionally substituted
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052731 fluorine Inorganic materials 0.000 claims description 59
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 58
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 58
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 56
- 239000011737 fluorine Substances 0.000 claims description 56
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 43
- 125000003118 aryl group Chemical group 0.000 claims description 26
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 23
- 229910052801 chlorine Inorganic materials 0.000 claims description 23
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 23
- 125000001424 substituent group Chemical group 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 18
- 125000001153 fluoro group Chemical group F* 0.000 claims description 16
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 14
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 6
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 6
- -1 or C 1 -C 6 alkyl Chemical group 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- 125000004434 sulfur atom Chemical group 0.000 claims description 6
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 4
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 150000002016 disaccharides Chemical class 0.000 claims description 4
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 150000002772 monosaccharides Chemical class 0.000 claims description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 2
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims description 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 2
- 229910014033 C-OH Inorganic materials 0.000 claims description 2
- 229910014570 C—OH Inorganic materials 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000006413 ring segment Chemical group 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229910052698 phosphorus Inorganic materials 0.000 claims 3
- 208000019622 heart disease Diseases 0.000 claims 2
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 claims 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000036737 immune function Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 150000008575 L-amino acids Chemical class 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461930031P | 2014-01-22 | 2014-01-22 | |
| US61/930,031 | 2014-01-22 | ||
| PCT/EP2015/000105 WO2015110262A1 (en) | 2014-01-22 | 2015-01-21 | Novel cyp-eicosanoid derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017505313A JP2017505313A (ja) | 2017-02-16 |
| JP2017505313A5 true JP2017505313A5 (enExample) | 2019-08-29 |
| JP6577951B2 JP6577951B2 (ja) | 2019-09-18 |
Family
ID=52446335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016548269A Active JP6577951B2 (ja) | 2014-01-22 | 2015-01-21 | 新規ｃｙｐ−エイコサノイド誘導体 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US11130772B2 (enExample) |
| EP (1) | EP3097076B1 (enExample) |
| JP (1) | JP6577951B2 (enExample) |
| KR (1) | KR102392893B1 (enExample) |
| CN (2) | CN110950786A (enExample) |
| AU (1) | AU2015208416B2 (enExample) |
| BR (1) | BR112016016139B1 (enExample) |
| CA (1) | CA2934964C (enExample) |
| CY (1) | CY1122591T1 (enExample) |
| DK (1) | DK3097076T3 (enExample) |
| ES (1) | ES2738701T3 (enExample) |
| HR (1) | HRP20191315T1 (enExample) |
| HU (1) | HUE044703T2 (enExample) |
| LT (1) | LT3097076T (enExample) |
| MX (1) | MX368689B (enExample) |
| PL (1) | PL3097076T3 (enExample) |
| PT (1) | PT3097076T (enExample) |
| RS (1) | RS59218B1 (enExample) |
| RU (1) | RU2730512C2 (enExample) |
| SI (1) | SI3097076T1 (enExample) |
| SM (1) | SMT201900438T1 (enExample) |
| WO (1) | WO2015110262A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2952726T3 (es) * | 2015-07-22 | 2023-11-03 | Omeicos Therapeutics Gmbh | Análogos metabólicamente fuertes de CYP-eicosanoides para el tratamiento de enfermedad cardíaca |
| JP6944465B2 (ja) * | 2016-04-01 | 2021-10-06 | オメイコス セラピューティクス ゲーエムベーハー | 血管新生及び／又は炎症と関連する障害の治療又は予防における使用に対するｃｙｐ−エイコサノイドの類縁体 |
| KR102433731B1 (ko) * | 2016-04-01 | 2022-08-22 | 오메이코스 테라퓨틱스 게엠베하 | 혈관신생 및/또는 염증과 연관된 장애의 치료 또는 예방에서 사용하기 위한 cyp-에이코사노이드의 유사체 |
| CN109414408B (zh) * | 2016-05-16 | 2022-03-29 | 得克萨斯州大学系统董事会 | 阳离子磺酰胺氨基脂质和两亲性两性离子氨基脂质 |
| EP4436562A1 (en) | 2021-11-26 | 2024-10-02 | OMEICOS Therapeutics GmbH | Synthetic eicosanoid analogues for the treatment and prevention of diseases associated with increased gdf15 plasma concentration |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5753702A (en) | 1996-05-22 | 1998-05-19 | University Of Vermont | Arachidonic acid metabolite, 16-hete |
| US6395781B1 (en) | 1998-02-26 | 2002-05-28 | Mcw Research Foundation | 20-HETE antagonists and agonists |
| WO2002059072A2 (en) | 2001-01-02 | 2002-08-01 | New York Medical College | 12-hydroxy-eicosatrienoic acid analogs and methods of use thereof |
| WO2004080389A2 (en) * | 2003-03-07 | 2004-09-23 | Taisho Pharmaceutical Co., Ltd. | Hydroxyeicosadienamide compounds |
| WO2005123079A2 (en) * | 2004-06-14 | 2005-12-29 | 3M Innovative Properties Company | Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
| US20080306155A1 (en) | 2004-09-16 | 2008-12-11 | Roman Richard J | Method for treating renal disease |
| US20080095711A1 (en) | 2006-08-31 | 2008-04-24 | Falck John R | Modulators of Pulmonary Hypertension |
| US7550617B2 (en) | 2006-10-02 | 2009-06-23 | Medical College Of Georgia Research Institute | Compositions and methods for the treatment of renal and cardiovascular disease |
| GB0802116D0 (en) * | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
| EP2208720A1 (en) | 2009-01-13 | 2010-07-21 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Novel eicosanoid derivatives |
| EP2504311B1 (en) | 2009-11-25 | 2015-08-12 | Cytometix, Inc. | Arachidonic acid analogs and methods for analgesic treatment using same |
| SG194075A1 (en) * | 2011-04-06 | 2013-11-29 | Mcw Res Found Inc | Epoxyeicosatrienoic acid analogs and methods of making and using the same |
-
2015
- 2015-01-21 ES ES15702370T patent/ES2738701T3/es active Active
- 2015-01-21 HU HUE15702370 patent/HUE044703T2/hu unknown
- 2015-01-21 KR KR1020167022894A patent/KR102392893B1/ko active Active
- 2015-01-21 AU AU2015208416A patent/AU2015208416B2/en active Active
- 2015-01-21 MX MX2016009507A patent/MX368689B/es active IP Right Grant
- 2015-01-21 RS RSP20190960 patent/RS59218B1/sr unknown
- 2015-01-21 SM SM20190438T patent/SMT201900438T1/it unknown
- 2015-01-21 JP JP2016548269A patent/JP6577951B2/ja active Active
- 2015-01-21 CN CN201911170917.5A patent/CN110950786A/zh active Pending
- 2015-01-21 LT LTEP15702370.6T patent/LT3097076T/lt unknown
- 2015-01-21 DK DK15702370.6T patent/DK3097076T3/da active
- 2015-01-21 RU RU2016133336A patent/RU2730512C2/ru active
- 2015-01-21 CA CA2934964A patent/CA2934964C/en active Active
- 2015-01-21 EP EP15702370.6A patent/EP3097076B1/en active Active
- 2015-01-21 US US15/113,139 patent/US11130772B2/en active Active
- 2015-01-21 CN CN201580005451.7A patent/CN106061942B/zh active Active
- 2015-01-21 SI SI201530839T patent/SI3097076T1/sl unknown
- 2015-01-21 PL PL15702370T patent/PL3097076T3/pl unknown
- 2015-01-21 HR HRP20191315TT patent/HRP20191315T1/hr unknown
- 2015-01-21 WO PCT/EP2015/000105 patent/WO2015110262A1/en not_active Ceased
- 2015-01-21 BR BR112016016139-4A patent/BR112016016139B1/pt active IP Right Grant
- 2015-01-21 PT PT15702370T patent/PT3097076T/pt unknown
-
2019
- 2019-08-07 CY CY20191100843T patent/CY1122591T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5536229B2 (ja) | Ｈｃｖ併用療法 | |
| RU2017106795A (ru) | Новые составы ингибитора тирозинкиназы брутона | |
| JP2017505313A5 (enExample) | ||
| JP6462045B2 (ja) | スルフォラファンの単離及び精製 | |
| TWI463991B (zh) | 生長抑素（ｓｏｍａｔｏｓｔａｔｉｎ）或其類似物之持續釋放型藥學組成物 | |
| TWI710555B (zh) | 新穎水溶性前藥 | |
| EA026100B1 (ru) | Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2,6-диона и их фармацевтические композиции и применение | |
| RS56713B1 (sr) | Upotreba malononitrilamida za neuropatski bol | |
| CN103702973B (zh) | 胺基丙二醇类衍生物、其制备方法和其药物组合物与用途 | |
| JP2019515908A5 (enExample) | ||
| AU2018260616B2 (en) | Treating and preventing kidney damage | |
| RU2018101439A (ru) | Метаболически устойчивые аналоги cyp-эйкозаноидов для лечения кардиологических заболеваний | |
| RU2015118581A (ru) | Лиофилизированные препараты мелфалана флуфенамида | |
| ES2773674T3 (es) | Sofosbuvir en forma cristalina y procedimiento para su preparación | |
| EP3922251B1 (en) | Cancer immunotheraphy adjuvant | |
| JP2020079261A (ja) | （１Ｅ，４Ｅ）−２−アミノ−Ｎ，Ｎ−ジプロピル−８−（４−（ピロリジン−１−カルボニル）フェニル）−３Ｈ−ベンゾ［ｂ］アゼピン−４−カルボキサミドを含む固体形態、その組成物、およびその使用 | |
| EP3305305A2 (en) | Silicate containing compositions and methods of treatment | |
| RU2016133336A (ru) | Новые производные CYP-эйкозаноидов | |
| CN109956975A (zh) | 肝递送恩替卡韦前体药物核苷环磷酸酯化合物及应用 | |
| JP2009526834A5 (enExample) | ||
| CA2552855A1 (en) | Azabicyclooctan-3-one derivatives and use thereof | |
| JP2021501202A5 (enExample) | ||
| ES2671730T3 (es) | Terapia de combinación para el cáncer de ovario | |
| ES2641143T3 (es) | Una composición farmacéutica que comprende palmitoiletanolamida y citidina-difosfocolina | |
| CA3062883A1 (en) | Vaccine containing cancer cells inactivated by photodynamic treatment with metal-based coordination complexes, and immunotherapy method using same |